HeLa-Luc Cells
1 104,00 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | HeLa-Luc cells are a bioluminescent derivative of the human HeLa cervical adenocarcinoma cell line that have been engineered to constitutively express a luciferase reporter gene. Following administration of the luciferin substrate, these cells emit a quantifiable luminescent signal that directly correlates with viable cell number and metabolic activity. This feature enables sensitive, non-invasive monitoring of tumor cell proliferation, survival, and dissemination in both in vitro assays and in vivo imaging applications. HeLa-Luc cells retain the robust growth characteristics and epithelial morphology associated with parental HeLa cells while providing an additional optical readout for longitudinal experimental analysis. The luciferase-expressing phenotype makes HeLa-Luc cells particularly useful for xenograft and metastasis studies in immunocompromised animal models, where real-time bioluminescence imaging can be used to track tumor burden and therapeutic response over time. In cell-based assays, these cells are widely employed for high-throughput drug screening, cytotoxicity testing, evaluation of gene delivery systems, and studies of cancer cell signaling and apoptosis. The stable reporter expression also supports reproducible quantification in co-culture systems and experimental models requiring dynamic monitoring of cellular viability or transcriptional activity. As with parental HeLa cells, HeLa-Luc cells exhibit the genomic instability and high proliferative capacity characteristic of transformed cervical cancer cells associated with human papillomavirus type 18 (HPV-18). Experimental conditions, luciferase vector design, promoter selection, and selection strategy may vary between laboratories or commercial sources, potentially influencing reporter intensity and long-term expression stability. Researchers should therefore verify luciferase activity, growth kinetics, and phenotypic consistency under their specific culture and assay conditions prior to large-scale experimental use. |
|---|---|
| Organisme | Human |
| Tissu | Uterus, cervix |
| Maladie | Human papillomavirus-related endocervical adenocarcinoma |
Caractéristiques
| Âge | 30,5 years |
|---|---|
| Genre | Female |
| Origine ethnique | African American |
| Morphologie | Epithelial-like |
| Propriétés de croissance | Adherent |
Données réglementaires
| Référence | Hela-Luc (Cytion catalog number 305664) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_YA88 |
| Statut OGM | GMO-S1: This HeLa cell line contains a lentiviral-Luc reporter construct for bioluminescent monitoring of cervical cancer cell behavior. This classification applies only within Germany and may differ elsewhere. |
Données biomoléculaires
| Expression des protéines | Luc |
|---|---|
| Isoenzymes | G6PD, A |
| Sensibilité aux virus | Poliovirus 1, 2, 3, vesicular stomatitis (Indiana), encephalomyocarditis, adenovirus 5 |
| Transcriptase inverse | Negative |
| Produits | Keratin |
Manipulation
| Milieu de culture | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS and 1% NEAA |
| Réactif de dissociation | Accutase |
| Densité de semis | 1 to 3 x 104 cells/cm2 |
| Renouvellement des fluides | 2 to 3 times per week |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
Certificat d'analyse (CoA)
| Numéro de lot | Type de certificat | Date | Numéro de catalogue |
|---|---|---|---|
| 305664-010426 | Certificat d'analyse | 15. May. 2026 | 305664 |